User menu

شهر سلامت دستگاه ماساژور دستگاه بخور دستگاه فشارسنج

Call for abstract

You are here

Call for Abstracts

The Annual Conference and Update on Diagnostic Advances in PIDs will provide a venue for the presentation of the latest immune deficiency diseases and the pathogenesis of these defects in molecular terms.

How to Submit an Abstract

Abstract submission for the 2018 RCID Annual Conference is now open!

  • Abstracts submissions are collected through the online submission page or by email abstract submission  (abstractsubmission@rcidcong.ir).
  • There is no fee to submit an abstract.
  • Abstract submission will close Feb 29, 2018. All abstracts must be submitted in full by 11:59 pm CDT on February 29, 2018 to be considered.
  • Notification of selected Abstracts will take place in late January.

Click here to submit an abstract.

2018 Categories of Interest

The following is a list of categories of interest to RCID for abstract submission. This is not an inclusive list and abstracts on categories not listed will also be accepted.

  • Hematopoietic cell transplantation and gene therapy
  • Immune dysregulation in PID
  • Immune modulating therapies
  • Immunoglobulin replacement therapy
  • Infections in PIDs
  • Innate immunity
  • NK cell biology
  • Novel genetic etiologies of PIDs
  • Phenotypic and molecular spectrum of Primary Immune Deficiency
  • PID registries

Questions about the 2018 RCID Annual Conferance can be sent to info@rcidcon.ir

 

Policies for Abstract Submission

 

Copyright Policy

Abstracts should not include libelous or defamatory content. Material presented in abstracts should not violate any copyright laws. If figures/graphics/images have been taken from sources not copyrighted by the author, it is the author’s sole responsibility to secure the rights from the copyright holder in writing to reproduce those figures/graphics/images for both worldwide print and web publication. All reproduction costs charged by the copyright holder must be borne by the author.

 

Resubmission Policy

An abstract which has been previously published or presented at a national, regional or international meeting can only be submitted provided that there are new methods, findings, updated information or other valid reasons for submitting.

If preliminary or partial data have been published or presented previously, the submitting author will be required to provide details of the publication or presentation, along with a justification of why the abstract merits consideration by email to info@rcidcong.ir  for ICID 2018. This information will be considered by the Scientific Programme Committee when making final decisions.

If the author neglects to provide these required details and justification, or if evidence of previous publication or presentation is found, the abstract will be rejected.

 

Plagiarism

The congress organizers regard plagiarism as serious professional misconduct. All abstracts are screened for plagiarism and when identified, the abstract and any other abstracts submitted by the same author are rejected. In addition, the submitting author’s profile and scholarship application, in the case one has been submitted, will also be cancelled.

 

Ethical Research Declaration

The congress supports only research that has been conducted according to the protocol approved by the institutional or local committee on ethics in human investigation. Where no such committee exists, the research should have been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. The ICID 2018 Scientific Programme Committee may enquire further into ethical aspects when evaluating the abstracts.

 

Congress Embargo Policy

In the case of ICID 2018, as well as most scientific/medical congresses, all congress abstracts are released to delegates and media under a strict embargo policy. For any abstract driven presentation: Information about the oral abstracts may not be published until the full abstract appears on the ICID 2018 website (http://rcidcong.ir).

 

Abstract Submission Process

Congress Profile

Before submitting an abstract, authors must create a congress profile. More than one abstract can be submitted through the conference profile. After an abstract has been created, modifications can be made until the submission deadline.

Abstracts received after the deadline cannot be accepted. You will receive notification regarding acceptance by March 15, 2018. Together with the confirmation of acceptance of your abstract, authors will be requested to register for the congress.

 

Choosing a Track Category

During the submission process, you will be asked to select one theme category for your abstract. The theme category is the general heading under which the abstract will be reviewed and later published in the congress materials, if accepted. The theme category which best describes the subject of the abstract should be chosen.

 

Choosing Preferred Presentation Type or Format

During the submission process, you will be asked to select a presentation preference. Below are the types of presentation formats available.

 

Oral presentation (within general scientific sessions or New Frontier symposia)

The scheduled time for each oral presentation is 15 minutes, including 3 minutes discussion.

Poster presentation

Posters will be gathered, numbered and listed according to the congress topics. Authors must be present in the poster area to discuss their posters during poster receptions and when possible during break times. Detailed information will be sent with the acceptance letter.

Important Note to remember when submitting your abstract:

 

We strongly recommend for the presenter to also be the corresponding author as any re-assignments of papers after acceptance can only be made if the person being assigned to is registered and paid to attend the congress.

 

Abstract Structure

Abstracts in all themes should be structured chronologically in five sections: first Introduction; then Materials and Methods, Results, and Discussion (together, these three sections make up the paper's body); and finally, Conclusion.

The Introduction section clarifies the motivation for the work presented and prepares readers for the structure of the paper.

The Materials and Methods section provides sufficient detail for other scientists to reproduce the experiments presented in the paper. In some journals, this information is placed in an appendix, because it is not what most readers want to know first.

The Results and Discussion sections present and discuss the research results, respectively. They are often usefully combined into one section, however, because readers can seldom make sense of results alone without accompanying interpretation — they need to be told what the results mean.

The Conclusion section presents the outcome of the work by interpreting the findings at a higher level of abstraction than the Discussion and by relating these findings to the motivation stated in the Introduction. Explain the significance of your findings / outcomes and future implications of the results.

The following review criteria will be used:

Relevance of the proposed work to the field of biomaterials (research and education)

Clarity and scope of the study aim/hypothesis

Quality and completeness of the methodology

Integrity of the results and coherence of discussion

Contribution to the biomaterials field and literature

 

Character / Word Limits

The abstract text body is limited to 3000 (Approx 500 words) characters including spaces. Titles are limited to 400 characters including spaces. A maximum of three figures (in JPG, GIF or PNG with ideally 600 dpi) can be included. These will not count toward the word limit, nor will the information about authors, institutions and study groups. File size of 2 MB maximum for each figure.

 

Abstract Review

Submitted abstracts that provide a substantial contribution to the biomaterials field and literature and follow the published abstracts submission instructions will be accepted for review. All submitted abstracts will go through a blinded peer-review process carried out by an international review committee.

All abstracts will be reviewed (blinded) by at least three international referees. Reviewers will be selected by the organizing committee. All reviewers will be asked to sign a statement addressing the impartiality and fairness of their review and state that there are no conflicts of interest with the authors, the work, sponsorship, or subject matter.

Abstracts which do not meet the focus of the topic or symposium category as requested by the authors will be reassigned to other symposia or category.

Each reviewer will identify a score for each abstract. A score of 1 to 10 will be assigned, based upon the following criteria: (i) relevance of the proposed work to the field of biomaterials (research and education), (ii) clarity and scope of the study aim/hypothesis, (iii) quality and completeness of the methodology, (iv) integrity of the results and coherence of discussion, and (v) contribution to the biomaterials field and literature.

Scores assigned by all reviewers are averaged. The cut-off average score for acceptance is based on available podium and poster presentations. Rejections are further evaluated by the program committee.

Notification of Acceptance or Rejection to Corresponding Author

Notification of acceptance or rejection will be sent to the submitting (corresponding) author by March 15, 2015. Please note that only the corresponding author will receive mail concerning the abstract and is responsible for informing all co-authors of the status of the abstract. Authors whose abstracts have been accepted will receive instructions for the presentation of their abstract.

GET IN TOUCH

  • Research Center for Immunodeficiencies
    Children's Medical Center Hospital
    62 Qarib St, Keshavarz Blvd,Tehran 14194, Iran
  • Phone: +98 21 6643 8622
  • Email: info@rcidcong.ir